Adiponectin as a therapeutic target for obesity-related metabolic and cardiovascular disorders
Article first published online: 16 NOV 2006
© 2006 Wiley-Liss, Inc.
Drug Development Research
Special Issue: New Drugs for Metabolic Syndrome. Part II: Invited Reviews
Volume 67, Issue 8, pages 677–686, August 2006
How to Cite
Wang, Y., Lam, K. S.L. and Xu, A. (2006), Adiponectin as a therapeutic target for obesity-related metabolic and cardiovascular disorders. Drug Dev. Res., 67: 677–686. doi: 10.1002/ddr.20141
- Issue published online: 16 NOV 2006
- Article first published online: 16 NOV 2006
- Hong Kong Research Grant Council. Grant Number: N_HKU 727/05.
- cardiovascular disease;
Obesity is the major risk factor for the metabolic syndrome, which encompasses a cluster of inter-related metabolic risk factors for type 2 diabetes mellitus (T2DM), atherosclerosis, and cardiovascular diseases. Adiponectin, a major adipokine secreted from adipocytes, plays an important role in obesity-related metabolic and cardiovascular diseases. Longitudinal studies from different ethnic groups have identified low levels of plasma adiponectin (hypoadiponectinemia) to be an independent risk factor for T2DM, hypertension, and coronary artery diseases. On the other hand, results from various animal models have demonstrated the role of adiponectin as an insulin-sensitizer with potent anti-diabetic, anti-atherogenic, anti-inflammatory, and cardio-protective activities. Therefore, upregulation of endogenous adiponectin production by pharmacological and/or dietary interventions might have multiple beneficial effects on obesity-related disorders. A number of pharmacological agents that increase adiponectin production have recently been identified. Among them, the anti-diabetic actions of the PPARγ agonists, thiazolidinediones (TZDs), are mediated, at least in part, by induction of adiponectin expression. Here, we summarize the recent progress on clinical and pharmacological studies of adiponectin, and discuss the utility of adiponectin as a target to develop novel therapies for treatment and prevention of obesity-related metabolic and cardiovascular diseases. Drug Dev. Res. 67:677–686, 2006. © 2006 Wiley-Liss, Inc.